Article information
Full text is only aviable in PDF
Bibliografía
[1.]
A.G. Turpie, J.R. Leclerc.
Prophylaxis of venous thromboembolism.
Venous thromboembolic disorders., pp. 303-345
[2.]
Consensus Conference Prevention of venous thrombosis, pulmonary embolism, 256 (1986), pp. 744-749
[3.]
T.M. Hyers, R.D. Hull, J.G. Weg.
Antithrombotic therapy for venous thromboembolic disease.
Chest, 95 (1989), pp. 37-55
[4.]
J. Hirsh, M. Levine, A.G. Turpie.
Prévention de la maladie thrombo-embolique.
Embolie pulmonaire et thrombose veineuse profonde., pp. 167-183
[5.]
G.E. Roskob, R.D. Hull.
Practical approach for preventing venous thromboembolism.
Clinical thrombosis., pp. 91-106
[6.]
A.S. Gallus.
Anticoagulants in the prevention of venous thromboembolism.
En: Hirsch J, editores. Antithrombotic therapy. Baillière's Clinical Haematology, 3 (1990), pp. 651-684
[7.]
J. Hirsh, R.D. Hull.
A practical approach to the profilaxis of venous thromboembolism. En: Venous thromboembolism: natural history.
diagnosis and management, CRC Pres, (1987), pp. 117-129
[8.]
G.P. Clagett, J.S. Resich.
Prevention of venous thromboembolism in general surgical patients: results of meta-analysis.
Ann Surg, 208 (1988), pp. 227-240
[9.]
G.P. Clagett, F.A. Anderson, M.K. Levine, E.W. Salzaman, H.B. Wheeler.
Prevention of venous thromboembolism.
Chest, 102 (1992), pp. 391-407
[10.]
R. Collins, A. Scrimgeour, S. Yusuf, R. Peto.
Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopaedic, and urologic surgery.
N Engl J Med, 318 (1988), pp. 1.162-1.173
[11.]
Thromboembolic Risk Factors Consensus Group.
Risk of and profilaxis for venous thromboembolism in hospital patients.
BMJ, 305 (1992), pp. 567-574
[12.]
T.I. Morgenthaler, J.H. Ryu.
Clinical characteristics of fatal pulmonary embolism in a referral hospital.
Mayo Clin Proc, 70 (1995), pp. 417-424
[13.]
Rasmussen MS, Wille-Jorgensen P, Jorgensen LN. Postoperative fatal pulmonary embolism in a general surgical department. in press.
[14.]
F.A. Anderson, H.B. Wheeler, R.J. Goldberg, D.W. Hosmer, A. Forcier.
The prevalence of risk factors for venous thromboembolism among hospital patients.
Arch Intern Med, 152 (1992), pp. 1.660-1.664
[15.]
M. Monreal, J. Ruiz, A. Olazábal, A. Arias, J. Roca.
Deep venous thrombosis and the risk of pulmonary embolism. A systematic study.
Chest, 102 (1992), pp. 677-681
[16.]
F.A. Anderson, H.B. Wheeler.
Venous thromboembolism. Risk factors and prophylaxis.
Clin Chest Med, 16 (1995), pp. 235-251
[17.]
A. Cogo, E. Bernardi, P. Prandoni, B. Girolami, F. Noventa, P. Simioni, et al.
Acquired risk factors for deep vein thrombosis in symptomatic outpatients.
Arch Intern Med, 154 (1994), pp. 164-168
[18.]
M. Monreal, A. Raventós, R. Lerma, J. Ruiz, E. Lafoz, A. Alatrué, et al.
Pulmonary embolism in patients with upper extremity DVT associated to venous central lines: a prospective study.
Thromb Haemost, 72 (1994), pp. 548-550
[19.]
R.L. Nachman, R. Silverstein.
Hypercoagulable state.
Ann Intern Med, 199 (1993), pp. 819-823
[20.]
P.S. Wells, A.W.A. Lensing, J. Hirsch.
Graduated compression stockings in the prevention of postoperative venous thromboembolism. A metaanalysis.
Arch Intern Med, 154 (1994), pp. 67-72
[21.]
J. Hirsh.
Heparin.
N Engl J Med, 324 (1991), pp. 1.565-1.574
[22.]
J. Hirsh, J.E. Dalen, D. Deykin, L. Poller.
Heparine: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy an safety.
Chest, 102 (1992), pp. 337-351
[23.]
T.E. Warkentin, M.N. Levine, J. Hirsh, P. Horsewood, R.S. Roberts, M. Tech, et al.
Heparin-induced thrombocytopenia in patients treated with low-molecular-weight-heparin or unfractioned heparin.
N Engl J Med, 332 (1995), pp. 1.330-1.335
[26.]
J. Fareed, J. Walenga, D. Hoppensteadt, A. Racanelli, E. Coyne.
Chemical and biological heterogeneity in low molecular weight heparins: implications for clinical use and standardization.
Sem Thromb Haemost, 15 (1989), pp. 440-463
[27.]
M.N. Levine, J. Hirsh.
Clinical potential of low molecular weight heparins.
Baillière's Clinical Haematology, 3 (1990), pp. 545-553
[28.]
S. Coccheri.
Low molecular weight heparins: an introduction.
Haemostasis, 20 (1990), pp. 74-80
[29.]
C. Kearon, J. Hirsh.
Starting prophylaxis for venous thromboembolism postoperadvely.
Arch Intern Med, 155 (1995), pp. 366-372
[30.]
D. Bergqvist, U.S. Burmark, J. Frisell, T. Hallböök, B. Lindblad, B. Risberg, et al.
Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis.
Br J Surg, 73 (1986), pp. 204-208
[31.]
D. Bergqvist, T. Mätzsch, U.S. Burmark, J. Frisell, O. Guilbaud, T. Hallböök, et al.
Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis.
Br J Surg, 75 (1988), pp. 888-891
[32.]
A.G.G. Turpie, M.N. Levine, J. Hirsh, C.J. Carter, R.M. Jay, P.J. Powers, et al.
A randomized controlled trial of a low-molecular-weight heparin (enoxiparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery.
N Engl J Med, 315 (1986), pp. 925-929
[33.]
S. Haas, G. Blümel.
Prophylaxis of thromboembolism with various low-molecular-weight heparins.
Haemostasis, 18 (1988), pp. 82-87
[34.]
G. Pezzuoli, G.G. Neri, P.G. Settembrini, G. Coggi, N. Olivari, G. Buzetti, et al.
Effectiveness and safety of the low-molecular-weigth heparin CY 216 in the prevention of fatal pulmonary embolism and thromboembolic death in general surgery.
Haemostasis, 20 (1990), pp. 193-204
[35.]
V.V. Kakkar, B. Djazaeri, J. Fok, M. Fletcher.
Low-molecularweight heparin and prevention of postoperative deep vein thrombosis.
BMJ, 284 (1982), pp. 375-379
[36.]
A. Leizorovicz, M.C. Haugh, F.-R. Chapuis, M.M. Samama.
Boissel J-P. Low molecular weight heparin in prevention of perioperative thrombosis.
BMJ, 305 (1992), pp. 913-920
[37.]
M.T. Nurmohamed, F.R. Rosendaal, H.R. Briller, E. Dekker, D.W. Hommes, J.P. Vanderbroucke.
Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a metaanalysis.
Lancet, 340 (1992), pp. 152-156
[38.]
S. Haas, P. Haas.
Efficacy of low molecular weight heparins: an overview.
Semin Thromb Haemost, 19 (1993), pp. 101-106
[39.]
D. Bergqvist.
Perioperative hemorrhagic complications in patients on low molecular weight heparins.
Semin Thromb Hemost, 19 (1993), pp. 128-130
[40.]
D. Bergqvist, U.S. Burmark, P.A. Flordal, J. Frisell, T. Hallbook, M. Hedberg, et al.
Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2.500 versus 5.000 Xal units in 2.070 patients.
Br J Surg, 82 (1995), pp. 496-501
[41.]
S. Haas, C.W. Flosbach.
Prevention of postoperative thromboembolism with enoxaparin in general surgery: a german multicenter trial.
Semin Thromb Hemost, 19 (1993), pp. 164-173
[42.]
V.V. Kakkar, A.T. Cohen, R.A. Edmonson, M.J. Phillips, D.J. Cooper, S.K. Das, et al.
Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery.
Lancet, 341 (1993), pp. 259-265
[43.]
R. Hull, G. Raskob, G. Pineo, D. Rosenbloom, W. Evans, T. Mallory, et al.
A comparison of subcutaneous low-molecular-weight heparing with warfarin sodium for thromboembolism against deepvein thrombosis after hip or knee implantation.
N Engl J Med, 329 (1993), pp. 1.370-1.376
[44.]
M.M. Bern, J.J. Lokich, S.R. Wallach, A. Bothe, P.N. Benotti, C.F. Arkin, et al.
Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial.
Ann Intern Med, 112 (1990), pp. 423-428
[45.]
Antiplatelet Trialists Collaboration.
Collaborative overview of randomised trials of antiplatelet therapy-III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgial and medical patients.
BMJ, 308 (1994), pp. 235-246
[46.]
J. Hirsh, J.E. Dalen, V. Fuster, L.B. Harker, E.W. Salzman.
Aspirin and other platelet-active drugs. The relationship between dose, effectiveness and side effects.
Chest, 102 (1992), pp. 327-336
[47.]
B.I. Eriksson, P. Kälebo, S. Ekman, R. Kerry, M. Baur, D. Bach, et al.
Effective prevention of thromboembolic complications after total hip replacement with three different doses of recombinant hirudin, CGP 39393 (Revasc). Ciba, compared to unfractioned heparin.
Circulation, 90 (1994), pp. 3.066
[49.]
S. Ziomek, R.C. Read, G. Tobler, J.E. Harrell, J.C. Gocio, L.M. Fink, et al.
Throembolism in patients undergoing thoracotomy.
Ann Thorac Surg, 56 (1993), pp. 223-227
[50.]
D.N. Mohr, M.D. Silverstein, P.A. Murtaugh, J.M. Harrisob.
Prophylactic agents using venographic assessment.
Arch Intern Med, 153 (1993), pp. 2.221-2.228
[51.]
M. Drummond, M. Aristides, L. Davies, C. Forbes.
Economic evaluation of standard heparing and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery.
Br J Surg, 81 (1994), pp. 1.742-1.746
[52.]
J.R. Leclerc, W. Geerts.
Prevention of deep vein thrombosis after major knee surgery: a randomized, double-blind trial comparing a low-molecular-weight heparin (enoxaparin) to placebo.
Thromb Haemost, 67 (1992), pp. 417-423
[53.]
D. Bergqvist, S.E. Bergentz, S. Bornmyr, B. Husberg, P. Konrad, H. Lungner, et al.
Deep-vein thrombosis after renal transplantation: a prospective analysis of frequency and risk factors.
Eur Surg Res, 17 (1985), pp. 69-74
[54.]
J.S. Ginsberg, C.J. Hirsh.
Use of antithrombotic agents during pregnancy.
Chest, 102 (1992), pp. 385-390
[55.]
E. Melissari, C.J. Parker, N.V. Wilson, G. Monte, C. Kanthou, K.D. Pemberton, et al.
Use of low molecular weight heparin in pregnancy.
Thromb Haemost, 68 (1992), pp. 652-656
[56.]
W.H. Geerts, K.I. Code, R.M. Jay, E. Chen, J.P. Szalai.
A prospective study of venous thromboembolism after major trauma.
N Engl J Med, 331 (1994), pp. 1.601-1.606
[57.]
U. Spannagel, P. Kujath.
Low molecular weight heparin for the prevention of thromboembolism in out patients inmobilized by plaster cast.
Semin Thromb Haemost, 19 (1993), pp. 131-141
[58.]
A.G.G. Turpie, M. Gent, R. Côte, M.N. Levine, J.S. Ginsberg, P.J. Powers, et al.
A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep venous thrombosis in patients with acute ischemic stroke. A randomized, doubleblind study.
Ann Intern Med, 117 (1992), pp. 353-357
[59.]
D. Green, M.Y. Lee, A.C. Lim, J.S. Chmiel, M. Vetter, T. Pang, et al.
Prevention of thromboembolism after spinal word injury using low-molecular-weight heparin.
Ann Intern Med, 113 (1990), pp. 571-574
[60.]
A.K. Kakkar, R.C.N. Williamson.
Thromboprophylaxis in malignant disease.
Br J Surg, 82 (1995), pp. 742-745
Copyright © 1996. Sociedad Española de Neumología y Cirugía Torácica
